Form 4: Provectus Biopharmaceuticals CEO Edward Pershing Reports Conversion of Convertible Note into Preferred Stock

CEO Edward Pershing reports the conversion of an 8% unsecured convertible promissory note into Series D-1 Convertible Preferred Stock.

Summary

• On January 30, 2025, Edward Pershing, CEO of Provectus Biopharmaceuticals, filed a Form 4.
• The filing reports the conversion of an 8% unsecured convertible promissory note into 51,290 shares of Series D-1 Convertible Preferred Stock.
• The conversion occurred on January 30, 2024, at a price of $2.862 per share.
• Each share of Series D-1 Preferred Stock is convertible into 10 shares of common stock.
• The Series D-1 Convertible Preferred Stock will automatically convert into common stock on June 20, 2026, unless earlier converted.
• Following the reported transaction, Pershing beneficially owns 1,990,000 shares of Series D-1 Convertible Preferred Stock and 1,799,634 shares of common stock.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing, reflecting a routine transaction. It doesn't inherently convey positive or negative sentiment.

Future Outlook

The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on June 20, 2026, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D-1 Convertible Preferred Stock.

Industry Context

Form 4 filings are a routine part of regulatory compliance for company insiders and provide transparency into their transactions in the company's securities.

Stakeholder Impact

• The conversion of preferred stock to common stock could potentially dilute existing shareholders' equity.

Key Dates